Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Industry veteran Dixon Boardman celebrates 25 years of Optima

Friday, May 31, 2013

amb
Dixon Boardman
by Beverly Chandler, Opalesque London:

1988 saw Dixon Boardman establish one of the first independent funds of hedge funds in the US, Optima Fund Management. Some 25 years later the firm has $3.8bn under management for investors across the world drawn from institutions and high net worth individuals on a 60/40 split.

Boardman describes his business as being built on two essential principles: invest with the 'best and brightest’, and adhere to a stringent approach to risk management. "Innovation has been our hallmark since Day One," says Boardman. "Optima was on the cutting edge when we launched our first single manager fund, the Platinum Fund, with one of the true stars of the business, Kerr Neilson back in 1994." According to the databases, Neilson’s Platinum Fund has recorded a net annualised return of 11.5% to end March 2013. Boardman adds: "We were also on the cutting edge when we started to build customized programs for institutions in 1999 and have also been very innovative in recognizing compelling niche opportunities."

Two recent examples of such niche opportunities are the Optima Partners Focus Fund and The American Farmland Company. Launched in 2007, the Focus Fund enables investors to invest with a highly select group of accomplished hedge fund managers, each running a concentrated portfolio of their 'best ideas’.

The Focus Fund is one of Optima’s newest award winners, having gained top spot ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for